Global Follicle Stimulating Hormone Market Growth 2025-2031

The global Follicle Stimulating Hormone market size is predicted to grow from US$ 1318 million in 2025 to US$ 1565 million in 2031; it is expected to grow at a CAGR of 2.9% from 2025 to 2031.

Follicle stimulating hormone (FSH) is a hormone made by the pituitary gland that affects the gonads (female ovaries and males testes). In females, it stimulates growth of the ovarian follicles.

Due to less pollution, recombinant FSH takes large proportion in market. In 2019, recombinant FSH takes about 82% of Poland follicle stimulating hormone consumption market share.

There are only several companies producing this product, such as Merck Serono, MSD, IBSA, Ferring, Livzon and Techwell etc. Merck Serono and MSD are Top 2 companies in the world. In 2019, Merck Serono takes about 55% of Poland follicle stimulating hormone revenue. MSD takes about 18% of Poland follicle stimulating hormone revenue.

LP Information, Inc. (LPI) ' newest research report, the “Follicle Stimulating Hormone Industry Forecast” looks at past sales and reviews total world Follicle Stimulating Hormone sales in 2024, providing a comprehensive analysis by region and market sector of projected Follicle Stimulating Hormone sales for 2025 through 2031. With Follicle Stimulating Hormone sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Follicle Stimulating Hormone industry.

This Insight Report provides a comprehensive analysis of the global Follicle Stimulating Hormone landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Follicle Stimulating Hormone portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Follicle Stimulating Hormone market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Follicle Stimulating Hormone and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Follicle Stimulating Hormone.

This report presents a comprehensive overview, market shares, and growth opportunities of Follicle Stimulating Hormone market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Recombinant FSH
Urinary FSH

Segmentation by Application:
Infertility Treatment
Assisted Reproductive Technology

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck Serono
MSD
IBSA
Ferring
Livzon
Techwell
GenSci
Gedeon Richter
Teva

Key Questions Addressed in this Report

What is the 10-year outlook for the global Follicle Stimulating Hormone market?

What factors are driving Follicle Stimulating Hormone market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Follicle Stimulating Hormone market opportunities vary by end market size?

How does Follicle Stimulating Hormone break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.